Empagliflozin (EMPA), a sodium‐glucose cotransporter 2 (SGLT2) inhibitor used for diabetes mellitus type II therapy, has demonstrated a beneficial role in improving cardiovascular outcomes for patients with heart failure. This evidence concerns the gene SLC5A2 and heart failure.